BNP Paribas Funds Health Care Innovators I CapitalisationRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 16.8 | 12.6 | 7.9 | -1.0 | 9.2 | |
+/-Cat | -0.6 | 3.2 | 12.6 | 2.1 | 5.4 | |
+/-B’mrk | - | -5.6 | 2.1 | 1.5 | 1.8 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 20/11/2024 | EUR 2061.42 | |
Day Change | 1.09% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0823417067 | |
Fund Size (Mil) 20/11/2024 | EUR 1753.23 | |
Share Class Size (Mil) 20/11/2024 | EUR 124.50 | |
Max Initial Charge | - | |
Ongoing Charge 29/04/2024 | 0.96% |
Investment Objective: BNP Paribas Funds Health Care Innovators I Capitalisation |
Increase the value of its assets over the medium term by investing in healthcare innovative companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Jon Stephenson 02/05/2016 | ||
Christian Fay 09/07/2018 | ||
Inception Date 17/05/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care 10/40 NR EUR | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BNP Paribas Funds Health Care Innovators I Capitalisation | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
UnitedHealth Group Inc | Healthcare | 7.66 |
Eli Lilly and Co | Healthcare | 7.35 |
AstraZeneca PLC | Healthcare | 7.01 |
Sanofi SA | Healthcare | 5.96 |
Boston Scientific Corp | Healthcare | 4.98 |
Increase Decrease New since last portfolio | ||
BNP Paribas Funds Health Care Innovators I Capitalisation |